Approach-avoidance tendencies in depression and childhood trauma: No effect of noradrenergic stimulation.
Adverse childhood experience
Approach-avoidance
Emotional processing
Locus coeruleus
Major depressive disorder
Noradrenaline
Norepinephrine
Yohimbine
Journal
Comprehensive psychoneuroendocrinology
ISSN: 2666-4976
Titre abrégé: Compr Psychoneuroendocrinol
Pays: England
ID NLM: 101774169
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
received:
09
04
2021
revised:
18
07
2021
accepted:
30
07
2021
entrez:
27
6
2022
pubmed:
28
6
2022
medline:
28
6
2022
Statut:
epublish
Résumé
Adverse childhood experiences (ACE) are a major risk factor for major depressive disorder (MDD) in later life. Both conditions are characterized by dysregulations in the noradrenergic system related which again could represent a mediating mechanism for deficits in affective processing and behavioral functioning. In this double-blind, placebo-controlled study we tested the hypothesis that ACE and MDD are characterized by aberrant approach-avoidance (AA) tendencies and that these are mitigated after noradrenergic stimulation with yohimbine. In a mixed-measures, fully crossed design, participants (N = 131, 73 women) with/without MDD and with/without ACE received a single-dose of yohimbine or placebo on different days, followed by an AA task. We found modulation of AA tendencies by the emotional valence of target images, yet there were no effects of group or treatment. From these results, we conclude that AA tendencies are not critically affected by MDD or ACE and that the noradrenergic system is not substantially involved in this behavior.
Identifiants
pubmed: 35757673
doi: 10.1016/j.cpnec.2021.100077
pii: S2666-4976(21)00051-5
pmc: PMC9216672
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100077Informations de copyright
© 2021 The Authors.
Déclaration de conflit d'intérêts
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
J Abnorm Psychol. 2004 Feb;113(1):121-35
pubmed: 14992665
PLoS One. 2018 Mar 16;13(3):e0193787
pubmed: 29547643
Dev Psychopathol. 2021 Jan 15;:1-12
pubmed: 33446284
Psychiatry Res. 2017 Oct;256:475-481
pubmed: 28715782
Prog Neuropsychopharmacol Biol Psychiatry. 2020 Jan 10;96:109751
pubmed: 31446157
J Psychiatr Res. 2020 Jun;125:136-143
pubmed: 32283407
Stress. 2013 Mar;16(2):191-201
pubmed: 22746337
Behav Res Methods. 2010 Feb;42(1):351-62
pubmed: 20160315
Psychiatry Res. 2014 Nov 30;219(3):513-7
pubmed: 25060832
J Behav Ther Exp Psychiatry. 2015 Mar;46:1-7
pubmed: 25164091
Front Psychiatry. 2017 Mar 17;8:42
pubmed: 28367128
Neurosci Biobehav Rev. 2012 Nov;36(10):2214-25
pubmed: 22910678
Clin Psychol Rev. 2020 Apr;77:101825
pubmed: 32143108
Neurosci Biobehav Rev. 2020 Apr;111:30-56
pubmed: 31954150
Psychoneuroendocrinology. 2021 Mar;125:105103
pubmed: 33360031
J Behav Ther Exp Psychiatry. 2015 Jun;47:84-91
pubmed: 25499772
Neurochem Int. 2020 May;135:104706
pubmed: 32092327